[HTML][HTML] Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Background & Aims IMbrave150 demonstrated that atezolizumab plus bevacizumab led to
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label …
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS)
and progression-free survival (PFS) versus sorafenib in patients with unresectable …
and progression-free survival (PFS) versus sorafenib in patients with unresectable …
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …
PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu… - The Lancet …, 2021 - thelancet.com
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …
[HTML][HTML] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
RS Finn, S Qin, M Ikeda, PR Galle… - … England Journal of …, 2020 - Mass Medical Soc
Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …
antitumor activity and safety in a phase 1b trial involving patients with unresectable …
[PDF][PDF] IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab+ bevacizumab vs sorafenib in patients with …
IMbrave150: updated overall survival data from a global, randomized, open-label Phase III
study of atezolizumab + bevacizumab vs Page 1 IMbrave150: updated overall survival data …
study of atezolizumab + bevacizumab vs Page 1 IMbrave150: updated overall survival data …
[HTML][HTML] Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study
Background IMbrave150 has established the superiority of atezolizumab plus bevacizumab
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …
[HTML][HTML] IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for …
Background Ph 1b data has shown promising efficacy and safety for atezo+ bev in
unresectable HCC pts who have not received prior systemic therapy. Here, we report the …
unresectable HCC pts who have not received prior systemic therapy. Here, we report the …
Characterization of response to atezolizumab+ bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
R Salem, D Li, N Sommer, S Hernandez… - Cancer …, 2021 - Wiley Online Library
Background IMbrave150 is a phase III trial that assessed atezolizumab+ bevacizumab
(ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular …
(ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular …
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein… - The Lancet …, 2020 - thelancet.com
Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
F Jost‐Brinkmann, M Demir, A Wree… - Alimentary …, 2023 - Wiley Online Library
Summary Background and Aims Phase III trials have established atezolizumab plus
bevacizumab as the novel standard of care for patients with unresectable hepatocellular …
bevacizumab as the novel standard of care for patients with unresectable hepatocellular …